Lv11
16 积分 2022-12-09 加入
Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance
1小时前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
2小时前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
15天前
已完结
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
2个月前
已完结
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
2个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
3个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
3个月前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
6个月前
已完结
Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery
7个月前
已完结
JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
7个月前
已完结
皖公网安备34019202002308
